Search results for "Active metabolite"

showing 10 items of 22 documents

Postmortem distribution of dihydrocodeine and metabolites in a fatal case of dihydrocodeine intoxication.

1998

A report of a fatal dihydrocodeine ingestion under substitution therapy is given. Quantitation of dihydrocodeine, dihydromorphine, N-nordihydrocodeine, dihydrocodeine-6-, dihydromorphine-6- and dihydromorphine-3-glucuronide was performed simultaneously after solid-phase extraction prior to HPLC analysis, and the analytes were detected using their native fluorescence. Postmortem concentrations of blood samples from different sampling sites as well as from liver, kidney and cerebrum are reported. A hair sample was investigated to prove long-term use of the substitute drug. Site-to-site differences of the analytes from blood samples were very small. The partition behavior of the opioid glucuro…

AdultMaleMetaboliteDihydromorphineHematocritKidneyGas Chromatography-Mass SpectrometryPathology and Forensic Medicinechemistry.chemical_compoundFatal OutcomePharmacokineticsMedicineHumansActive metaboliteChromatography High Pressure LiquidBrain ChemistryMorphine DerivativesChromatographymedicine.diagnostic_testbusiness.industryCodeineCodeineDihydrocodeineAnalgesics OpioidchemistryLiverAnesthesiaDihydromorphinePostmortem ChangesToxicitybusinessLawBlood Chemical Analysismedicine.drugHairForensic science international
researchProduct

A systematic review and combined analysis of therapeutic drug monitoring studies for longacting risperidone

2017

Introduction: This systematic review of therapeutic drug monitoring (TDM) identifies three long-acting injectable (LAI) risperidone formulations. Areas covered: Limited data is available on two formulations (RBP-7000 and in Situ Microparticle), but 20 TDM articles on the microsphere formulation were found. Risperidone TDM includes the serum concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, used for calculating: 1) the risperidone/9-hydroxyrisperidone (R/9-OH-R) ratio (a measure of CYP2D6; values >1 are indicative of a CYP2D6 poor metabolizer) and 2) the total risperidone concentration-to-dose (C/D) ratio (a measure of risperidone clearance with a normal value…

CYP2D6Therapeutic drug monitoring studiesAdministration OralPharmacologyMicrosphereInjections03 medical and health sciences0302 clinical medicineLong acting risperidonePaliperidone PalmitatemedicineAnimalsHumansPharmacology (medical)General Pharmacology Toxicology and Pharmaceutics610 Medicine & healthActive metabolitePaliperidone PalmitateRisperidonemedicine.diagnostic_testbusiness.industryGeneral MedicineRisperidoneMicrospheres030227 psychiatryAntipsychotic agents/administration & dosage; delayed-action preparations; drug monitoring; injections; risperidone/administration & dosage; risperidone/blood; risperidone/metabolism; risperidone/pharmacokinetics; risperidone/pharmacology; risperidone/therapeutic use; schizophrenia/drug therapyTherapeutic drug monitoringDelayed-Action PreparationsDrug Monitoringbusiness030217 neurology & neurosurgerymedicine.drugAntipsychotic Agents
researchProduct

INULIN BASED HYDROGEL FOR ORAL DELIVERY OF FLUTAMIDE: PREPARATION, CHARACTERIZATION AND IN VIVO RELEASE STUDIES

2012

The ability of a hydrogel obtained by crosslinking INUDV and PEGBa to facilitate sustained release of flutamide is examined. The hydrogel is prepared in pH = 7.4 PBS and no toxic solvents or catalysts are used. It is recovered in microparticulate form and its size distribution is determined. Mucoadhesive properties are evaluated in vitro by reproducing gastrointestinal conditions. Flutamide is loaded into the hydrogel using a post-fabrication encapsulation procedure that allows a drug loading comparable to that of market tablets. Drug-loaded microparticles are orally administered to cross-bred dogs and the in vivo study demonstrates their ability to prolong the half-life of the principal ac…

MalePolymers and PlasticsInulinAdministration OralBiological AvailabilityBioengineeringPharmacologyFlutamideBiomaterialschemistry.chemical_compoundDogsDrug Delivery SystemsIn vivoMaterials ChemistryDistribution (pharmacology)AnimalsHypoglycemic AgentsInsulinActive metabolitetechnology industry and agricultureAndrogen AntagonistsHydrogelsIn vitroFlutamideBioavailabilitychemistrySelf-healing hydrogelsBiotechnologyHalf-Life
researchProduct

Substantial Fat Loss in Physique Competitors Is Characterized by Increased Levels of Bile Acids, Very-Long Chain Fatty Acids, and Oxylipins.

2022

Funder: Finnish Foundation for Cardiovascular Research

LC-MS metabolomeexercisekuntoliikuntalaihdutusvisceral fat massliikuntaweight lossbioactive metabolitesaineenvaihduntafyysinen aktiivisuusArticlepainonhallinta
researchProduct

Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

2021

Atorvastatin (ATS) is the gold-standard treatment worldwide for the management of hypercholesterolemia and prevention of cardiovascular diseases associated with dyslipidemia. Physiologically based pharmacokinetic (PBPK) models have been positioned as a valuable tool for the characterization of complex pharmacokinetic (PK) processes and its extrapolation in special sub-groups of the population, leading to regulatory recognition. Several PBPK models of ATS have been published in the recent years, addressing different aspects of the PK properties of ATS. Therefore, the aims of this review are (i) to summarize the physicochemical and pharmacokinetic characteristics involved in the time-course o…

Physiologically based pharmacokinetic modellingModel predictionAtorvastatinPopulationPharmaceutical ScienceReviewTarget populationComputational biologyP-glycoprotein030226 pharmacology & pharmacy03 medical and health sciencesPharmacy and materia medica0302 clinical medicinePharmacokineticsmedicineopen acid formeducationeducation.field_of_studybusiness.industrysolubilityatorvastatinactive metabolitesRS1-441lactonizationDose optimizationMetabolic enzymes030220 oncology & carcinogenesisbusinessmedicine.drugPharmaceutics
researchProduct

Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphat…

2015

Iontophoresis has been used to deliver small molecules, peptides and proteins into and across the skin. In principle, it provides a controlled, non-invasive method for poly-pharmacotherapy since it is possible to formulate and to deliver multiple therapeutic agents simultaneously from the anodal and cathodal compartments. The objective of this proof-of-principle study was to investigate the simultaneous anodal iontophoretic delivery of granisetron (GST) and metoclopramide (MCL) and cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P). In addition to validating the hypothesis, these are medications that are routinely used in combination to treat chemotherapy-induced emesis. Two p…

MaleMetoclopramideSwinePharmaceutical Science02 engineering and technologyPharmacologyGranisetronAdministration Cutaneous030226 pharmacology & pharmacyDexamethasoneGranisetron03 medical and health sciences0302 clinical medicineDexamethasone Sodium PhosphatePharmacokineticsIn vivomedicineAnimalsRats WistarDexamethasoneActive metaboliteTransdermalSkinIontophoresisChemistryHydrolysisIontophoresis021001 nanoscience & nanotechnologyRatsPolypharmacy0210 nano-technologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects

2007

Aripiprazole, a novel antipsychotic drug, is metabolized by CYP3A4 and CYP2D6 forming mainly its active metabolite dehydroaripiprazole. In this study, aripiprazole and dehydroaripiprazole serum levels of psychiatric patients were measured and related to dose, comedication, and clinical effects including therapeutic and side effects. Patients were treated with mean doses of 20 +/- 8 mg/day of aripiprazole (median 15 mg, range 7.5-60 mg). Serum levels correlated significantly with the dose (r = 0.419; P0.01), with a mean value of aripiprazole of 214 +/- 140 ng/ml. Mean concentrations of the active metabolite dehydroaripiprazole amounted to 40% of the parent compound. Comedication with CYP3A4 …

AdultMaleCYP2D6AripiprazoleQuinolonesPharmacologydigestive systemPiperazinesCytochrome P-450 CYP3AHumansMedicineAntipsychotic drugskin and connective tissue diseasesDehydroaripiprazoleBiological PsychiatryActive metaboliteAgedCYP3A4medicine.diagnostic_testbusiness.industryMiddle AgedPsychiatry and Mental healthCytochrome P-450 CYP2D6Therapeutic drug monitoringSchizophreniaFemaleAripiprazolebusinessAntipsychotic Agentsmedicine.drugThe World Journal of Biological Psychiatry
researchProduct

Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease

2013

Background Glucocorticoid functions are markedly impaired in patients with chronic obstructive pulmonary disease (COPD). The phosphodiesterase 4 inhibitor roflumilast N-oxide (RNO) is the active metabolite of roflumilast approved as a treatment to reduce the risk of exacerbations in patients with severe COPD. Objective We sought to characterize the differential effects of RNO versus corticosteroids and their potential additive/synergistic effect in neutrophils from patients with COPD, thus providing scientific rationale for the combination of roflumilast with corticosteroids in the clinic. Methods Peripheral blood neutrophils were isolated from patients with COPD (n = 32), smokers (n = 7), …

CyclopropanesLipopolysaccharidesMaleMAPK/ERK pathwaymedicine.medical_specialtyNeutrophilsPrimary Cell CultureImmunologyDrug ResistanceAminopyridinesGene ExpressionComplex MixturesDexamethasoneHistone DeacetylasesPhosphatidylinositol 3-KinasesPulmonary Disease Chronic ObstructiveGlucocorticoid receptorAdrenal Cortex HormonesInternal medicineTobaccomedicineHumansImmunology and AllergyMacrophage Migration-Inhibitory FactorsDexamethasoneActive metaboliteRoflumilastAgedCOPDbusiness.industryInterleukin-8Drug SynergismMiddle Agedmedicine.diseaseIntramolecular OxidoreductasesEndocrinologyMatrix Metalloproteinase 9BenzamidesMitogen-Activated Protein Kinase PhosphatasesFemaleMacrophage migration inhibitory factorPhosphodiesterase 4 InhibitorsbusinessBiomarkersGlucocorticoidmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Variations of essential oil constituents in oregano (Origanum vulgare subsp. viridulum (= o. heracleoticum) over cultivation cycles

2020

Oregano is&mdash

0106 biological sciencesHarvest timearomatic plants cultivationPlant Science01 natural sciencesessential oillaw.inventionactive metabolitechemistry.chemical_compoundlawthymolThymolSicilyEcology Evolution Behavior and SystematicsEssential oilEcologybiology010405 organic chemistryBotanyactive metabolitesOriganumbiology.organism_classification0104 chemical sciencesSettore AGR/02 - Agronomia E Coltivazioni ErbaceeHorticulturechemistryQK1-989Composition (visual arts)oreganoharvest time010606 plant biology & botany
researchProduct

Inhibition of Mycotoxigenic Fungi in Different Vegetable Matrices by Extracts of Trichoderma Species

2021

Post-harvest fungal diseases of plant products are a serious concern leading to economic losses and health risks. Moreover, the use of synthetic chemical fungicides to prevent these diseases is limited due to toxic residues. This study aimed at determining the effective dose of extracts of Trichoderma&nbsp

Microbiology (medical)Ochratoxin AAflatoxinTrichoderma asperellumQH301-705.5Biological pest controlbiological controlPlant ScienceBiologyArticlechemistry.chemical_compoundmycotoxinsFood scienceTrichoderma atrovirideBiology (General)MycotoxinEcology Evolution Behavior and Systematicsfood and beveragesContaminationTrichoderma asperellumEffective dose (pharmacology)<i>Trichoderma</i> <i>atroviride</i>FungicideTrichoderma atroviridechemistry<i>Trichoderma</i> <i>asperellum</i>bioactive metabolitesTrichoderma speciesJournal of Fungi
researchProduct